相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial
J. O'Shaughnessy et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
A phase I study of ABT-888 (A) in combination with metronomic cyclophosphamide (C) in adults with refractory solid tumors and lymphomas.
S. Kummar et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Sunitinib (SU) in combination with docetaxel (D) versus D alone for the first-line treatment of advanced breast cancer (ABC).
J. Bergh et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Sorafenib (SOR) plus chemotherapy (CRx) for patients (pts) with advanced (adv) breast cancer (BC) previously treated with bevacizumab (BEV).
C. Hudis et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40.
H. D. Bear et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
A phase II pilot trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node positive breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group
K. D. Miller et al.
ANNALS OF ONCOLOGY (2012)
Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer
Gunter von Minckwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Triple negative breast cancer: unmet medical needs
Sumanta Kumar Pal et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial
Mogens Bernsdorf et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Relative contributions of BRCA1 and BRCA2 mutations to triple-negative breast cancer in Ashkenazi Women
E. Comen et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Impact of Exploratory Biomarkers on the Treatment Effect of Bevacizumab in Metastatic Breast Cancer
Adrian M. Jubb et al.
CLINICAL CANCER RESEARCH (2011)
Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer
Ana M. Gonzalez-Angulo et al.
CLINICAL CANCER RESEARCH (2011)
Characteristics of triple-negative breast cancer
Tim C. de Ruijter et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2011)
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
Brian D. Lehmann et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC).
J. O'Shaughnessy et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
TBCRC009: A multicenter phase II study of cisplatin or carboplatin for metastatic triple-negative breast cancer and evaluation of p63/p73 as a biomarker of response
S. J. Isakoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Open label, randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC (T-FEC) versus the combination of paclitaxel and RAD001 followed by FEC (TR-FEC) in women with triple receptor-negative breast cancer (TNBC)
A. M. Gonzalez-Angulo et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Congestive Heart Failure Risk in Patients With Breast Cancer Treated With Bevacizumab
Toni K. Choueiri et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Avastin Hearing Leads to More Uncertainty Over Drug's Future
Merrill Goozner
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
Karen A. Gelmon et al.
LANCET ONCOLOGY (2011)
Deconstructing the molecular portraits of breast cancer
Aleix Prat et al.
MOLECULAR ONCOLOGY (2011)
Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer.
Joyce O'Shaughnessy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Molecular Stratification of Triple-Negative Breast Cancers
Charles M. Perou
ONCOLOGIST (2011)
SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer
E. L. Mayer et al.
ANNALS OF ONCOLOGY (2010)
Weekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer
X. S. Chen et al.
ANNALS OF ONCOLOGY (2010)
Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer
H. Wildiers et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer
Carlos H. Barrios et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
SOLTI-0701: A Multinational Double-Blind, Randomized Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo When Administered in Combination with Capecitabine in Patients with Locally Advanced or Metastatic Breast Cancer (BC).
J. Baselga et al.
CANCER RESEARCH (2010)
Potential Predictive Markers of Benefit from Cetuximab in Metastatic Breast Cancer: An Analysis of Two Randomized Phase 2 Trials.
L. Carey et al.
CANCER RESEARCH (2010)
Comparison of Subgroup Analyses of PFS from Three Phase III Studies of Bevacizumab in Combination with Chemotherapy in Patients with HER2-Negative Metastatic Breast Cancer (MBC).
J. O'Shaughnessy et al.
CANCER RESEARCH (2010)
Results of a Phase II Study of Neoadjuvant Platinum/Taxane Based Chemotherapy and Erlotinib for Triple Negative Breast Cancer
P. Sharma et al.
CANCER RESEARCH (2010)
Overall Survival Data from SOLTI-0701: A Multinational, Double-Blind, Placebo-Controlled, Randomized Phase 2b Study Evaluating the Oral Combination of Sorafenib and Capecitabine in Patients with Locally Advanced or Metastatic HER2-Negative Breast Cancer
P. Gomez et al.
CANCER RESEARCH (2010)
Sorafenib in Combination with Paclitaxel as a First-Line Therapy in Patients with Locally Recurrent or Metastatic Breast Cancer: Overall Survival Results from a Double-Blind, Randomized, Placebo-Controlled, Phase 2b Trial
S. Bondarde et al.
CANCER RESEARCH (2010)
Meta-Analysis of Patients with Triple-Negative Breast Cancer (TNBC) from Three Randomized Trials of First-Line Bevacizumab (BV) and Chemotherapy Treatment for Metastatic Breast Cancer (MBC)
J. O'Shaughnessy et al.
CANCER RESEARCH (2010)
A Randomized Phase II Study of Sunitinib vs. Standard of Care for Patients with Previously Treated Advanced Triple-Negative Breast Cancer
G. Curigliano et al.
CANCER RESEARCH (2010)
Cetuximab plus Cisplatin in Estrogen Receptor-Negative, Progesterone Receptor-Negative, HER2-Negative (Triple-Negative) Metastatic Breast Cancer: Results of the Randomized Phase II BALI-1 Trial
J. Baselga et al.
CANCER RESEARCH (2010)
Transcriptome Analysis of Triple Negative Breast Cancers Identifies Six Distinct Biological Subgroups and Reveals Therapeutic Strategies
B. D. Lehmann et al.
CANCER RESEARCH (2010)
Low-dose metronomic chemotherapy with cisplatin: can it suppress angiogenesis in H22 hepatocarcinoma cells?
Fang-Zhen Shen et al.
INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY (2010)
Phase I Study of Everolimus Plus Weekly Paclitaxel and Trastuzumab in Patients With Metastatic Breast Cancer Pretreated With Trastuzumab
Fabrice Andre et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Preliminary results of a phase I trial of ABT-888, a poly(ADP-ribose) polymerase (PARP) inhibitor, in combination with cyclophosphamide.
A. R. Tan et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase III trial of sunitinib (SU) in combination with capecitabine (C) versus C in previously treated advanced breast cancer (ABC)
J. Crown et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
Daniel P. Silver et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer.
S. J. Isakoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Safety and efficacy of the oral PARP inhibitor olaparib (AZD2281) in combination with paclitaxel for the first- or second-line treatment of patients with metastatic triple-negative breast cancer: Results from the safety cohort of a phase I/II multicenter trial.
R. A. Dent et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Magnitude of risks and benefits of the addition of bevacizumab (BEVA) to chemotherapy (CT) for patients (pts) with advanced breast cancer (ABC): Metaregression analysis of randomized trials (RCT)
F. Cuppone et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Use of SPARC, EGFR, and VEGFR expression to predict response to nab-paclitaxel (nabP)/carboplatin (C)/bevacizumab (B) chemotherapy in triple-negative metastatic breast cancer (TNMBC).
E. P. Hamilton et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
A phase I combination study of olaparib (AZD2281; KU-0059436) and cisplatin (C) plus gemcitabine (G) in adults with solid tumors.
G. Giaccone et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Pathologic Complete Response Rates in Young Women With BRCA1-Positive Breast Cancers After Neoadjuvant Chemotherapy
Tomasz Byrski et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
Andrew Tutt et al.
LANCET (2010)
Triple-Negative Breast Cancer
William D. Foulkes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer
G. Frasci et al.
ANNALS OF ONCOLOGY (2009)
Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer
B. K. Linderholm et al.
ANNALS OF ONCOLOGY (2009)
Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer
Giulia Bianchi et al.
ANTI-CANCER DRUGS (2009)
Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
T. Byrski et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Invasive ductal carcinoma of the breast with the triple-negative phenotype: prognostic implications of EGFR immunoreactivity
Giuseppe Viale et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Survival Outcomes for Patients with Metastatic Triple-Negative Breast Cancer: Implications for Clinical Practice and Trial Design
Farrah Kassam et al.
CLINICAL BREAST CANCER (2009)
Single institute phase II study of weekly cisplatinum and metronomic dosing of endoxan and methotrexate in second line metastatic breast cancer triple-negative
G. S. Bhattacharyya et al.
EJC SUPPLEMENTS (2009)
Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors
Ana M. Mendes-Pereira et al.
EMBO MOLECULAR MEDICINE (2009)
Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases
Florian Heitz et al.
EUROPEAN JOURNAL OF CANCER (2009)
Phase II Trial of Sorafenib in Patients With Metastatic Breast Cancer Previously Exposed to Anthracyclines or Taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336
Alvaro Moreno-Aspitia et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Dose-Dense Adjuvant Doxorubicin and Cyclophosphamide Is Not Associated With Frequent Short-Term Changes in Left Ventricular Ejection Fraction
Patrick G. Morris et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Estrogen Receptor, Progesterone Receptor, Human Epidermal Growth Factor Receptor 2 (HER2), and Epidermal Growth Factor Receptor Expression and Benefit From Lapatinib in a Randomized Trial of Paclitaxel With Lapatinib or Placebo As First-Line Treatment in HER2-Negative or Unknown Metastatic Breast Cancer
Richard S. Finn et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Breast Cancer Subtypes and Response to Docetaxel in Node-Positive Breast Cancer: Use of an Immunohistochemical Definition in the BCIRG 001 Trial
Judith Hugh et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers.
Peter C. Fong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Platinum-based chemotherapy in triple-negative breast cancer
B. Sirohi et al.
ANNALS OF ONCOLOGY (2008)
Subtypes of breast cancer show preferential site of relapse
Marcel Smid et al.
CANCER RESEARCH (2008)
Phase II trial of gemcitabine/carboplatin (plus trastuzumab in HER2-positive disease) in patients with metastatic breast cancer
David Loesch et al.
CLINICAL BREAST CANCER (2008)
Cisplatin Versus Carboplatin in NSCLC: Is There One Best Answer?
Rachel E. Sanborn
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2008)
How basal are triple-negative breast cancers?
Francois Bertucci et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Basal-like subtype and BRCA1 dysfunction in breast cancers
Yasuo Miyoshi et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2008)
Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer
Deann P. Atchley et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer
L. A. Carey et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the arimidex, tamoxifen, alone or in combination trial
Mitch Dowsett et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100
Bryan P. Schneider et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane
Harold J. Burstein et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer
Cornelia Liedtke et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Epidemiology of basal-like breast cancer
Robert C. Millikan et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients
David S. P. Tan et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel
Rosalba Torrisi et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
Kathy Miller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Triple-negative breast cancer: Clinical features and patterns of recurrence
Rebecca Dent et al.
CLINICAL CANCER RESEARCH (2007)
Descriptive analysis of estrogen receptor (ER)negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype - A population-based study from the California Cancer Registry
Katrina R. Bauer et al.
CANCER (2007)
BRCA1 dysfunction in sporadic basal-like breast cancer
N. C. Turner et al.
ONCOGENE (2007)
Prognostic markers in triple-negative breast cancer
Emad A. Rakha et al.
CANCER (2007)
Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas
Bas Kreike et al.
BREAST CANCER RESEARCH (2007)
Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer
Bruce G. Haffty et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study
Lisa A. Carey et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
The molecular portraits of breast tumors are conserved across microarray platforms
Zhiyuan Hu et al.
BMC GENOMICS (2006)
High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses
DM Abd El-Rehim et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Determinants of rapamycin sensitivity in breast cancer cells
WC Noh et al.
CLINICAL CANCER RESEARCH (2004)
The prognostic implication of the basal-like (cyclin Ehigh/p27low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer
WD Foulkes et al.
CANCER RESEARCH (2004)
Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma
TO Nielsen et al.
CLINICAL CANCER RESEARCH (2004)
Hallmarks of 'BRCAness' in sporadic cancers
N Turner et al.
NATURE REVIEWS CANCER (2004)
Repeated observation of breast tumor subtypes in independent gene expression data sets
T Sorlie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
T Sorlie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer
K Yu et al.
ENDOCRINE-RELATED CANCER (2001)
Homologous recombinational repair of DNA ensures mammalian chromosome stability
LH Thompson et al.
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS (2001)
Genome maintenance mechanisms for preventing cancer
JHJ Hoeijmakers
NATURE (2001)
Identification of Id4 as a regulator of BRCA1 expression by using a ribozyme-library-based inverse genomics approach
C Beger et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Base excision repair is impaired in mammalian cells lacking poly(ADP-ribose) polymerase-1
F Dantzer et al.
BIOCHEMISTRY (2000)
分享论文
